SG11201807591VA - Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof - Google Patents
Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofInfo
- Publication number
- SG11201807591VA SG11201807591VA SG11201807591VA SG11201807591VA SG11201807591VA SG 11201807591V A SG11201807591V A SG 11201807591VA SG 11201807591V A SG11201807591V A SG 11201807591VA SG 11201807591V A SG11201807591V A SG 11201807591VA SG 11201807591V A SG11201807591V A SG 11201807591VA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- avenue
- crystalline
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/156009 Al 14 September 2017 (14.09.2017) WIPO I PCT (51) International Patent Classification: CO7D 261/18 (2006.01) A61P 9/00 (2006.01) A61K 31/42 (2006.01) (21) International Application Number: PCT/US2017/021172 (22) International Filing Date: 7 March 2017 (07.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/305,393 8 March 2016 (08.03.2016) US 62/346,336 6 June 2016 (06.06.2016) US (71) Applicant: THERAVANCE BIOPHARMA R&D IP, LLC [US/US]; 901 Gateway Boulevard, South San Fran- cisco, California 94080 (US). (72) Inventors: HUGHES, Adam D.; 2029 Touraine Lane, Half Moon Bay, California 94019 (US). FLEURY, Melissa; 47D Joy Avenue, Brisbane, California 94005 (US). RAPTA, Miroslav; 1240 Highland Court, San Car- los, California 94070 (US). THALLADI, Venkat R.; 888 Foster City Boulevard, Apt. E3, Foster City, California 94404 (US). FASS, Gene Timothy; 998 Burnett Avenue, San Francisco, California 94131 (US). SIMEONE, Mi- chael; 75 Heather Avenue #6, San Francisco, California 94118 (US). BALDWIN, R. Michael; 1720 2nd Avenue, San Mateo, California 94401 (US). BOURDET, David L.; 614 Bayview Avenue, Millbrae, California 94030 (US). (74) Agents: HAGENAH, Jeffrey A. et al.; THERAVANCE BIOPHARMA US, INC., 901 Gateway Boulevard, South San Francisco, California 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) — (54) Title: CRYSTALLINE(2S,4R)-5-(5'-CHLOR0-2'-FLUOR041,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HY- DROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF OW N OH 0 HO CI (I), , (57) : In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystal- line form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I') forms. 1111111111111101110101011111010111110 011111111100111111101110111111111110111111 W O 20 17 / 15 6009 Al
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305393P | 2016-03-08 | 2016-03-08 | |
| US201662346336P | 2016-06-06 | 2016-06-06 | |
| PCT/US2017/021172 WO2017156009A1 (en) | 2016-03-08 | 2017-03-07 | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807591VA true SG11201807591VA (en) | 2018-10-30 |
Family
ID=58387911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807591VA SG11201807591VA (en) | 2016-03-08 | 2017-03-07 | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US10100021B2 (en) |
| EP (1) | EP3408260B1 (en) |
| JP (2) | JP7306828B2 (en) |
| KR (2) | KR20220035991A (en) |
| CN (1) | CN108779084A (en) |
| AU (1) | AU2017229466C1 (en) |
| BR (1) | BR112018068170A2 (en) |
| CA (1) | CA3015505C (en) |
| CL (1) | CL2018002539A1 (en) |
| CO (1) | CO2018010568A2 (en) |
| CY (1) | CY1124397T1 (en) |
| DK (1) | DK3408260T3 (en) |
| ES (1) | ES2880123T3 (en) |
| HR (1) | HRP20211169T1 (en) |
| HU (1) | HUE055546T2 (en) |
| IL (1) | IL261244B (en) |
| LT (1) | LT3408260T (en) |
| MX (1) | MX2018010727A (en) |
| PH (1) | PH12018501876A1 (en) |
| PL (1) | PL3408260T3 (en) |
| PT (1) | PT3408260T (en) |
| RS (1) | RS62172B1 (en) |
| RU (1) | RU2756223C2 (en) |
| SA (1) | SA518392325B1 (en) |
| SG (1) | SG11201807591VA (en) |
| SI (1) | SI3408260T1 (en) |
| TW (1) | TWI731943B (en) |
| WO (1) | WO2017156009A1 (en) |
| ZA (1) | ZA201805840B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10100021B2 (en) | 2016-03-08 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
| EP4032532A4 (en) * | 2019-09-20 | 2023-10-04 | Shenzhen Salubris Pharmaceuticals Co. Ltd | Uses of complex of angiotensin ii receptor antagonist metabolite and nep inhibitor in treating heart failure |
| KR102485499B1 (en) * | 2022-07-15 | 2023-01-09 | 오가노이드사이언스 주식회사 | Composition for treating or preventing kidney disease |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| US4206232A (en) | 1976-05-10 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Relieving hypertension with carboxyalkylacylamino acids |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| FR2480747A1 (en) | 1980-04-17 | 1981-10-23 | Roques Bernard | AMINO ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATION |
| US4906615A (en) | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4939261A (en) | 1984-06-08 | 1990-07-03 | Ciba-Geigy Corporation | N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase |
| EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| KR880007441A (en) | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | Spiro-Substituted Glutaramide Diuretics |
| FR2623498B1 (en) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | NOVEL ENANTIOMERIC COMPOUNDS DERIVED FROM AMINO ACIDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS |
| GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
| US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| DE19510566A1 (en) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepine, benzoxazepine and benzothiazepine N-acetic acid derivatives and process for their preparation and medicaments containing these compounds |
| WO1996033170A1 (en) | 1995-04-21 | 1996-10-24 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
| WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| AR057882A1 (en) | 2005-11-09 | 2007-12-26 | Novartis Ag | DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS |
| US20070204367A1 (en) | 2006-02-17 | 2007-08-30 | Stanislaw Flasinski | Chimeric regulatory sequences comprising introns for plant gene expression |
| WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| MY151993A (en) | 2007-01-12 | 2014-07-31 | Novartis Ag | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid |
| TWI448284B (en) | 2007-04-24 | 2014-08-11 | Theravance Inc | Dual-acting antihypertensive agents |
| PE20091364A1 (en) | 2008-01-17 | 2009-10-13 | Novartis Ag | PROCESS FOR THE PREPARATION OF NEP INHIBITORS |
| MX2011012627A (en) | 2009-05-28 | 2011-12-14 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors. |
| KR101442897B1 (en) | 2009-05-28 | 2014-09-23 | 노파르티스 아게 | Substituted aminopropionic derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
| SI2526088T1 (en) | 2010-01-22 | 2015-12-31 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
| KR101892500B1 (en) | 2010-12-15 | 2018-08-28 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Neprilysin inhibitors |
| WO2012082857A1 (en) | 2010-12-15 | 2012-06-21 | Theravance, Inc. | Neprilysin inhibitors |
| MY163394A (en) | 2011-02-17 | 2017-09-15 | Theravance Biopharma R&D Ip Llc | Substituted aminobutyric derivates as neprilysin inhibitors |
| WO2012154249A1 (en) | 2011-02-17 | 2012-11-15 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
| JP5959074B2 (en) | 2011-05-31 | 2016-08-02 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Neprilysin inhibitor |
| CA2835281A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| CN103582630B (en) | 2011-05-31 | 2016-08-17 | 施万生物制药研发Ip有限责任公司 | Enkephalinase inhibitor |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| ES2609810T3 (en) | 2012-05-31 | 2017-04-24 | Theravance Biopharma R&D Ip, Llc | Nitric oxide donor neprilysin inhibitors |
| WO2013184934A1 (en) | 2012-06-08 | 2013-12-12 | Theravance, Inc. | Neprilysin inhibitors |
| ES2710932T3 (en) | 2012-06-08 | 2019-04-29 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| PT2882716T (en) * | 2012-08-08 | 2017-03-13 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| WO2014202493A1 (en) * | 2013-06-19 | 2014-12-24 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives |
| CA2934936A1 (en) * | 2014-01-30 | 2015-08-06 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
| US10100021B2 (en) | 2016-03-08 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
-
2017
- 2017-03-07 US US15/452,333 patent/US10100021B2/en active Active
- 2017-03-07 TW TW106107450A patent/TWI731943B/en active
- 2017-03-07 DK DK17712605.9T patent/DK3408260T3/en active
- 2017-03-07 PL PL17712605T patent/PL3408260T3/en unknown
- 2017-03-07 CA CA3015505A patent/CA3015505C/en active Active
- 2017-03-07 KR KR1020227008251A patent/KR20220035991A/en not_active IP Right Cessation
- 2017-03-07 AU AU2017229466A patent/AU2017229466C1/en active Active
- 2017-03-07 EP EP17712605.9A patent/EP3408260B1/en active Active
- 2017-03-07 JP JP2018546864A patent/JP7306828B2/en active Active
- 2017-03-07 SI SI201730845T patent/SI3408260T1/en unknown
- 2017-03-07 MX MX2018010727A patent/MX2018010727A/en active IP Right Grant
- 2017-03-07 KR KR1020187028757A patent/KR20180114225A/en not_active IP Right Cessation
- 2017-03-07 RS RS20210963A patent/RS62172B1/en unknown
- 2017-03-07 SG SG11201807591VA patent/SG11201807591VA/en unknown
- 2017-03-07 BR BR112018068170A patent/BR112018068170A2/en active IP Right Grant
- 2017-03-07 CN CN201780016076.5A patent/CN108779084A/en active Pending
- 2017-03-07 HU HUE17712605A patent/HUE055546T2/en unknown
- 2017-03-07 LT LTEP17712605.9T patent/LT3408260T/en unknown
- 2017-03-07 PT PT177126059T patent/PT3408260T/en unknown
- 2017-03-07 RU RU2018135072A patent/RU2756223C2/en active
- 2017-03-07 ES ES17712605T patent/ES2880123T3/en active Active
- 2017-03-07 WO PCT/US2017/021172 patent/WO2017156009A1/en active Application Filing
-
2018
- 2018-08-20 IL IL261244A patent/IL261244B/en unknown
- 2018-08-30 ZA ZA2018/05840A patent/ZA201805840B/en unknown
- 2018-09-02 SA SA518392325A patent/SA518392325B1/en unknown
- 2018-09-03 PH PH12018501876A patent/PH12018501876A1/en unknown
- 2018-09-05 CL CL2018002539A patent/CL2018002539A1/en unknown
- 2018-09-10 US US16/125,991 patent/US10472335B2/en active Active
- 2018-10-02 CO CONC2018/0010568A patent/CO2018010568A2/en unknown
-
2019
- 2019-09-25 US US16/582,051 patent/US10752599B2/en active Active
-
2020
- 2020-07-14 US US16/928,206 patent/US11230536B2/en active Active
-
2021
- 2021-07-21 HR HRP20211169TT patent/HRP20211169T1/en unknown
- 2021-07-30 CY CY20211100685T patent/CY1124397T1/en unknown
- 2021-10-29 JP JP2021177448A patent/JP2022017433A/en active Pending
- 2021-12-14 US US17/550,564 patent/US11718591B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201804587QA (en) | Isoindole compounds |